Preliminary outcomes of the European multicentre experience with the ZSI 375 artificial urinary sphincter for treatment of stress urinary incontinence in men.

The ZSI 375 is a new artificial urinary sphincter utilised in men suffering from stress urinary incontinence (SUI). We present the first European multicentre study on the effectiveness of ZSI 375.

This study was conducted in a retrospective, non-randomized format in centres across Europe. Between May 2009 and December 2014, ZSI 375 was fitted in 109 SUI patients following radical prostatectomy, transurethral resection of prostate (TURP), rectal surgery and high intensity focused ultrasound (HIFU). Patients with history of pelvic radiotherapy or previous surgical treatment for incontinence or stricture were excluded from the series. Follow-up was completed by December 2016. The key outcome measures included overall improvement and complication rates.

A total of 109 patients in 10 European centres were recruited and had the ZSI 375 device implanted. The average patient age was 72 years old. The indication for the majority of patients was incontinence following radical prostatectomy (100/109 patients, 91.74%). On average, patients were incontinent for 48.6 months prior to treatment. All patients used ≥4 pads daily at baseline and thus were classified as suffering from 'severe incontinence'. The average follow-up until the final visit was 43 months. The pad usage decreased to 0.84 on average by the last visit. There were no reported cases of device infection. A total of 9 patients had urethral cuff erosion (8.25%),which was the most common complication in this series. A further 3 men (2.75%) experienced mechanical failure requiring subsequent device reimplantation. The implantation of the ZSI 375 device was considered successful in 92.66% of patients.

The ZSI 375 is an effective surgical treatment option in men with severe stress urinary incontinence.

Central European journal of urology. 2019 Jul 12 [Epub]

Ireneusz Ostrowski, Tomasz Golabek, Janusz Ciechan, Emil Śledź, Mikolaj Przydacz, Wojciech Dyś, Mariusz Blewniewski, Burkhard von Heyden, Tobias Pottek, Frank Neugart, Giuseppe Carrieri, Oscar Selvaggio, Francesco Iori, Manuel Fernández Arjona, Steve Foley, Bob Yang, Christophe Llorens, Waldemar Różanski, Piotr L Chłosta

Department of Urology and Urological Oncology, Regional Specialistic Hospital, Puławy, Poland., Department of Urology, Jagiellonian University, Medical College, Cracow, Poland., Department of General, Oncological and Functional Urology, II Clinic of Urology, Łódź, Poland., Urology Practice, Gaildorf, Germany., Department of Reconstructive Urology, Vivantes Urban Hospital, Berlin, Germany., Department of Urology, Baden-Baden, Germany., Department of Urology, Ospedali Riuniti, Foggia, Italy., Department of Urology, University Hospital Policlinic Umberto I, Rome, Italy., Department of Urology, Hospital de Henares, Madrit, Spain., Department of Urology, Reading, United Kingdom., Department of Urology, Reims, France.

Pelvic Health Weekly Newsletter